trending Market Intelligence /marketintelligence/en/news-insights/trending/HkjlpWjPKtQqyUMGIgG2CA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

ImmunoGen prices common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


ImmunoGen prices common stock offering

ImmunoGen Inc. priced an underwritten public offering of 14.5 million common shares at $6.50 apiece.

The company expects gross proceeds of about $94.3 million.

The company granted underwriters a 30-day option to buy up to an additional 2,175,000 common shares at the offering price.

The offering is expected to close by Oct. 11, subject to customary closing conditions.

ImmunoGen plans to use net proceeds to help fund its operations, commercialization preparation, acquisitions of new technologies, capital expenditures and working capital.

Jefferies, Leerink Partners and RBC Capital Markets are acting as joint book-running managers for the offering, with Canaccord Genuity as sole co-manager.